Get the Stockscreener App
49.19
1.15%
0.56
After Hours:
50.00
0.81
+1.65%
Supernus Pharmaceuticals Inc stock is traded at $49.19, with a volume of 1.11M.
It is up +1.15% in the last 24 hours and down -2.56% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
See More
Previous Close:
$48.63
Open:
$49.07
24h Volume:
1.11M
Relative Volume:
1.58
Market Cap:
$2.85B
Revenue:
$718.95M
Net Income/Loss:
$-38.55M
P/E Ratio:
-71.93
EPS:
-0.6839
Net Cash Flow:
$45.99M
1W Performance:
+1.03%
1M Performance:
-2.56%
6M Performance:
+4.42%
1Y Performance:
+51.87%
1-Day Range:
$48.10
$50.55
1-Week Range:
$47.17
$50.55
52-Week Range:
$29.16
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
49.19 | 2.82B | 718.95M | -38.55M | 45.99M | -0.6839 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Supernus Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Supernus outlines $840M-$870M 2026 revenue outlook as ONAPGO second-supplier filing targeted for Q3 - MSN
Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Supernus (SUPN) Q1 2026 Earnings Transcript - The Globe and Mail
Supernus Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
SUPERNUS PHARMACEUTICALS ($SUPN) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative
Four newer Supernus drugs bring in $149.1M as 2026 outlook holds - Stock Titan
[10-Q] SUPERNUS PHARMACEUTICALS, INC. Quarterly Earnings Report - Stock Titan
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat Estimates - Yahoo Finance
Supernus Announces First Quarter 2026 Financial Results - GlobeNewswire
Supernus faces earnings test as Onapgo launch gains traction - Investing.com
Supernus Pharmaceuticals Q1 2026 earnings preview - MSN
How Supernus Pharmaceuticals Inc. (SUPN) Affects Rotational Strategy Timing - Stock Traders Daily
Supernus Pharmaceuticals Earnings: What To Look For From SUPN - Yahoo Finance
[ARS] SUPERNUS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Supernus (NASDAQ: SUPN) sets 2026 virtual meeting on directors, pay and equity plan - Stock Titan
Vanguard (NASDAQ: SUPN) owns 2.9M Supernus shares, 5.03% stake - Stock Titan
Piper Sandler Upgrades Supernus Pharmaceuticals (SUPN) - MSN
Supernus finalizes $350M asset acquisition of Navitor’s SPN-820 - MSN
Vanguard Portfolio Management (NASDAQ: SUPN) holds 3.26M shares, 5.66% - Stock Titan
Supernus Signals Shift on Nasdaq Chart After Results - Kalkine Media
Branded Pharmaceuticals Stocks Q4 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) - Yahoo Finance
Pharmaceutical Company Sued For Antitrust Appeals No D&O Coverage Ruling - Mealey's
BofA cuts Supernus Pharmaceuticals stock price target on costs By Investing.com - Investing.com Canada
A Look At Supernus Pharmaceuticals (SUPN) Valuation After Strong Recent Shareholder Returns - simplywall.st
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise? - TradingView
(SUPN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
SUPN (Supernus Pharmaceuticals Inc.) delivers 142 percent Q4 2025 EPS surprise, shares rise 4.41 percent today.Shared Buy Zones - Cổng thông tin điện tử Tỉnh Sơn La
Supernus (SUPN) sets May 5 call to discuss Q1 2026 results - Stock Titan
Supernus will detail first-quarter results after markets close May 5 - Stock Titan
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference ... - Caledonian Record
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026 - GlobeNewswire
Supernus Pharmaceuticals (SUPN) Stock: Worth Holding? (Bearish Sentiment) 2026-04-20Community Momentum Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Latest SUPN NewsSupernus Announces First Quarter 2020 Finan... - Stock Titan
Supernus Pharmaceuticals (SUPN) Stock DCF Valuation (Creeps Higher) 2026-04-18Sector Leader - Xã Thanh Hà
Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Stock: Trend Direction (Trend Strengthens) 2026-04-18Community Buy Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Q4 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
MACD Signal: Is Supernus Pharmaceuticals Inc part of any major index2026 Year in Review & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Tudor Investment Corp ET AL Invests $1.43 Million in Supernus Pharmaceuticals - National Today
Responsive Playbooks and the SUPN Inflection - Stock Traders Daily
Supernus Pharmaceuticals, Inc. (SUPN) Stock forecasts - Yahoo Finance UK
Supernus Pharmaceuticals (SUPN) Enters $350M Asset Purchase Agre - GuruFocus
Supernus Pharmaceuticals Acquires NV-5138 (SPN-820) Compound from Navitor Pharmaceuticals in Asset Purchase Agreement - Minichart
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):